Sunday, 1 April 2012

NeoClarityn Oral Solution





1. Name Of The Medicinal Product



Neoclarityn 0.5 mg/ml oral solution


2. Qualitative And Quantitative Composition



Each ml of oral solution contains 0.5 mg desloratadine.



This medicinal product contains 150 mg/ml of sorbitol



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Oral solution



4. Clinical Particulars



4.1 Therapeutic Indications



Neoclarityn is indicated for the relief of symptoms associated with:



- allergic rhinitis (see section 5.1)



- urticaria (see section 5.1)



4.2 Posology And Method Of Administration



Neoclarityn may be taken without regard to mealtime for the relief of symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria (see section 5.1).



The prescriber should be aware that most cases of rhinitis below 2 years of age are of infectious origin (see section 4.4) and there are no data supporting the treatment of infectious rhinitis with Neoclarityn.



Children 1 through 5 years of age: 2.5 ml (1.25 mg) Neoclarityn oral solution once a day.



Children 6 through 11 years of age: 5 ml (2.5 mg) Neoclarityn oral solution once a day.



In adults and adolescents (12 years of age and over): 10 ml (5 mg) Neoclarityn oral solution once a day.



There is limited clinical trial efficacy experience with the use of desloratadine in adolescents 12 through 17 years of age (see sections 4.8 and 5.1).



Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient's disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.



In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure periods.



4.3 Contraindications



Hypersensitivity to the active substance, to any of the excipients, or to loratadine.



4.4 Special Warnings And Precautions For Use



Efficacy and safety of Neoclarityn oral solution in children under 1 year of age have not been established.



In children below 2 years of age, the diagnosis of allergic rhinitis is particularly difficult to distinguish from other forms of rhinitis. The absence of upper respiratory tract infection or structural abnormalities, as well as patient history, physical examinations, and appropriate laboratory and skin tests should be considered.



Approximately 6 % of adults and children 2- to 11-year old are phenotypic poor metabolisers of desloratadine and exhibit a higher exposure (see section 5.2). The safety of desloratadine in children 2- to 11-years of age who are poor metabolisers is the same as in children who are normal metabolisers. The effects of desloratadine in poor metabolisers < 2 years of age have not been studied.



In the case of severe renal insufficiency, Neoclarityn should be used with caution (see section 5.2).



This medicinal product contains sorbitol; thus, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



No clinically relevant interactions were observed in clinical trials with Neoclarityn tablets in which erythromycin or ketoconazole were co-administered (see section 5.1).



In a clinical pharmacology trial, Neoclarityn tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1).



4.6 Pregnancy And Lactation



Desloratadine was not teratogenic in animal studies. The safe use of the medicinal product during pregnancy has not been established. The use of Neoclarityn during pregnancy is therefore not recommended.



Desloratadine is excreted into breast milk, therefore the use of Neoclarityn is not recommended in breastfeeding women.



4.7 Effects On Ability To Drive And Use Machines



In clinical trials that assessed the driving ability, no impairment occurred in patients receiving desloratadine. However, patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines.



4.8 Undesirable Effects



In clinical trials in a paediatric population, the desloratadine syrup formulation was administered to a total of 246 children aged 6 months through 11 years. The overall incidence of adverse events in children 2 through 11 years of age was similar for the desloratadine and the placebo groups. In infants and toddlers aged 6 to 23 months, the most frequent adverse events reported in excess of placebo were diarrhoea (3.7 %), fever (2.3 %) and insomnia (2.3 %). In an additional study, no adverse events were seen in subjects between 6 and 11 years of age following a single 2.5 mg dose of desloratadine oral solution.



At the recommended dose, in clinical trials involving adults and adolescents in a range of indications including allergic rhinitis and chronic idiopathic urticaria, undesirable effects with Neoclarityn were reported in 3 % of patients in excess of those treated with placebo. The most frequent of adverse events reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %). Other undesirable effects reported very rarely during the post-marketing period are listed in the following table.


















Psychiatric disorders




Hallucinations




Nervous system disorders




Dizziness, somnolence, insomnia, psychomotor hyperactivity, seizures




Cardiac disorders




Tachycardia, palpitations




Gastrointestinal disorders




Abdominal pain, nausea, vomiting, dyspepsia, diarrhoea




Hepatobiliary disorders




Elevations of liver enzymes, increased bilirubin, hepatitis




Musculoskeletal and connective tissue disorders




Myalgia




General disorders




Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and urticaria)



4.9 Overdose



In the event of overdose, consider standard measures to remove unabsorbed active substance.



Symptomatic and supportive treatment is recommended.



Based on a multiple dose clinical trial in adults and adolescents, in which up to 45 mg of desloratadine was administered (nine times the clinical dose), no clinically relevant effects were observed.



Desloratadine is not eliminated by haemodialysis; it is not known if it is eliminated by peritoneal dialysis.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: antihistamines – H1 antagonist, ATC code: R06A X27



Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H1-receptor antagonist activity. After oral administration, desloratadine selectively blocks peripheral histamine H1-receptors because the substance is excluded from entry to the central nervous system.



Desloratadine has demonstrated antiallergic properties from in vitro studies. These include inhibiting the release of proinflammatory cytokines such as IL-4, IL-6, IL-8, and IL-13 from human mast cells/basophils, as well as inhibition of the expression of the adhesion molecule P-selectin on endothelial cells. The clinical relevance of these observations remains to be confirmed.



Efficacy of Neoclarityn oral solution has not been investigated in separate paediatric trials. However, the safety of Neoclarityn syrup, which contains the same concentration of desloratadine, was demonstrated in three paediatric trials. Children, 1-11 years of age, who were candidates for antihistamine therapy received a daily desloratadine dose of 1.25 mg (1 through 5 years of age) or 2.5 mg (6 through 11 years of age). Treatment was well tolerated as documented by clinical laboratory tests, vital signs, and ECG interval data, including QTc. When given at the recommended doses, the plasma concentrations of desloratadine (see section 5.2) were comparable in the paediatric and adult populations. Thus, since the course of allergic rhinitis/chronic idiopathic urticaria and the profile of desloratadine are similar in adults and paediatric patients, desloratadine efficacy data in adults can be extrapolated to the paediatric population.



In a multiple dose clinical trial, in adults and adolescents, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was observed. In a clinical pharmacology trial, in adults and adolescents, in which desloratadine was administered to adults at a dose of 45 mg daily (nine times the clinical dose) for ten days, no prolongation of QTc interval was seen.



Desloratadine does not readily penetrate the central nervous system. In controlled clinical trials, at the recommended dose of 5 mg daily for adults and adolescents, there was no excess incidence of somnolence as compared to placebo. Neoclarityn tablets given at a single daily dose of 7.5 mg to adults and adolescents did not affect psychomotor performance in clinical trials. In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying.



In clinical pharmacology trials in adults, co-administration with alcohol did not increase the alcohol-induced impairment in performance or increase in sleepiness. No significant differences were found in the psychomotor test results between desloratadine and placebo groups, whether administered alone or with alcohol.



No clinically relevant changes in desloratadine plasma concentrations were observed in multiple-dose ketoconazole and erythromycin interaction trials.



Efficacy of Neoclarityn syrup has not been investigated in paediatric trials in children less than 12 years of age.



In adult and adolescent patients with allergic rhinitis, Neoclarityn tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate. Neoclarityn effectively controlled symptoms for 24 hours. The efficacy of Neoclarityn tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age.



In addition to the established classifications of seasonal and perennial, allergic rhinitis can alternatively be classified as intermittent allergic rhinitis and persistent allergic rhinitis according to the duration of symptoms. Intermittent allergic rhinitis is defined as the presence of symptoms for less than 4 days per week or for less than 4 weeks. Persistent allergic rhinitis is defined as the presence of symptoms for 4 days or more per week and for more than 4 weeks.



Neoclarityn tablets were effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire. The greatest amelioration was seen in the domains of practical problems and daily activities limited by symptoms.



Chronic idiopathic urticaria was studied as a clinical model for urticarial conditions, since the underlying pathophysiology is similar, regardless of etiology, and because chronic patients can be more easily recruited prospectively. Since histamine release is a causal factor in all urticarial diseases, desloratadine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria, as advised in clinical guidelines.



In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, Neoclarityn was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval. In each trial, the effects were sustained over the 24 hour dosing interval. As with other antihistamine trials in chronic idiopathic urticaria, the minority of patients who were identified as non-responsive to antihistamines was excluded. An improvement in pruritus of more than 50 % was observed in 55 % of patients treated with desloratadine compared with 19 % of patients treated with placebo. Treatment with Neoclarityn also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.



5.2 Pharmacokinetic Properties



Desloratadine plasma concentrations can be detected within 30 minutes of desloratadine administration in adults and adolescents. Desloratadine is well absorbed with maximum concentration achieved after approximately 3 hours; the terminal phase half-life is approximately 27 hours. The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency. The bioavailability of desloratadine was dose proportional over the range of 5 mg to 20 mg.



In a series of pharmacokinetic and clinical trials, 6 % of the subjects reached a higher concentration of desloratadine. The prevalence of this poor metaboliser phenotype was comparable for adult (6 %) and paediatric subjects 2- to 11-year old (6 %), and greater among Blacks (18 % adult, 16 % paediatric) than Caucasians (2 % adult, 3 % paediatric) in both populations.



In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine. These subjects had a Cmax concentration about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours.



Similar pharmacokinetic parameters were observed in a multiple-dose pharmacokinetic study conducted with the syrup formulation in paediatric poor metaboliser subjects 2- to 11-year old diagnosed with allergic rhinitis. The exposure (AUC) to desloratadine was about 6-fold higher and the Cmax was about 3 to 4 fold higher at 3-6 hours with a terminal half-life of approximately 120 hours. Exposure was the same in adult and paediatric poor metabolisers when treated with age-appropriate doses. The overall safety profile of these subjects was not different from that of the general population. The effects of desloratadine in poor metabolizers < 2 years of age have not been studied.



Desloratadine is moderately bound (83 % - 87 %) to plasma proteins. There is no evidence of clinically relevant active substance accumulation following once daily adult and adolescent dosing of desloratadine (5 mg to 20 mg) for 14 days.



In a single dose, crossover study of desloratadine, the tablet and the syrup formulations were found to be bioequivalent. As Neoclarityn oral solution contains the same concentration of desloratadine, no bioequivalence study was required and it is expected to be equivalent to the syrup and tablet.



In separate single dose studies, at the recommended doses, paediatric patients had comparable AUC and Cmax values of desloratadine to those in adults who received a 5 mg dose of desloratadine syrup.



The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other medicinal products can not be fully excluded. Desloratadine does not inhibit CYP3A4 in vivo, and in vitro studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein.



In a single dose trial using a 7.5 mg dose of desloratadine, there was no effect of food (high-fat, high caloric breakfast) on the disposition of desloratadine. In another study, grapefruit juice had no effect on the disposition of desloratadine.



5.3 Preclinical Safety Data



Desloratadine is the primary active metabolite of loratadine. Non-clinical studies conducted with desloratadine and loratadine demonstrated that there are no qualitative or quantitative differences in the toxicity profile of desloratadine and loratadine at comparable levels of exposure to desloratadine.



Non-clinical data with desloratadine reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction. The lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.



6. Pharmaceutical Particulars



6.1 List Of Excipients



sorbitol,



propylene glycol,



sucralose E 955,



hypromellose 2910,



sodium citrate dihydrate,



natural and artificial flavour (bubblegum),



citric acid anhydrous,



disodium edetate,



purified water



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



2 years



6.4 Special Precautions For Storage



Do not freeze. Store in the original package.



6.5 Nature And Contents Of Container



Neoclarityn oral solution, is supplied in 30, 50, 60, 100, 120, 150, 225 and 300 ml size Type III amber glass bottles closed with a plastic child resistant (C/R) screw closure having a multi-ply polyethylene-faced liner. All packages except the 150 ml package are supplied with a measuring spoon marked for doses of 2.5 ml and 5 ml. For the 150 ml package, a measuring spoon or an oral measuring syringe is provided, marked for doses of 2.5 ml and 5 ml.



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



No special requirements.



7. Marketing Authorisation Holder



Merck Sharp & Dohme Ltd



Hertford Road



Hoddesdon



Hertfordshire



EN11 9BU



United Kingdom



8. Marketing Authorisation Number(S)



EU/1/00/161/059-067



9. Date Of First Authorisation/Renewal Of The Authorisation



Date of first authorisation: 15 January 2001



Date of last renewal: 15 January 2006



10. Date Of Revision Of The Text



16 September 2011



Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/



11. LEGAL CATEGORY


Prescription Only Medicine



NeoClarityn Oral Sol/SPC/EU/09-11/04




Friday, 30 March 2012

Periostat


Pronunciation: DOX-i-SYE-kleen
Generic Name: Doxycycline
Brand Name: Periostat


Periostat is used for:

Treating periodontitis, a dental disease that attacks the gum, bone, and around the teeth.


Periostat is a tetracycline. It works to treat periodontitis by decreasing the activity of a certain enzyme (collagenase).


Do NOT use Periostat if:


  • you are allergic to any ingredient in Periostat or to another tetracycline (eg, minocycline)

  • you are taking acitretin, isotretinoin, methotrexate, or a blood thinner (eg, warfarin)

  • you have recently received or will be receiving a live oral typhoid vaccine

Contact your doctor or health care provider right away if any of these apply to you.



Before using Periostat:


Some medical conditions may interact with Periostat. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have diarrhea, a stomach infection, a history of lupus, or the blood disease porphyria

  • if you have a history of oral yeast infections

Some MEDICINES MAY INTERACT with Periostat. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Barbiturates (eg, phenobarbital), carbamazepine, cimetidine, colestipol, hydantoins (eg, phenytoin), or rifampin because they may decrease Periostat's effectiveness

  • Acitretin, digoxin, insulin,isotretinoin, methotrexate, methoxyflurane,blood thinners (eg, warfarin), or theophylline because the risk of their side effects may be increased by Periostat

  • Live oral typhoid vaccine, hormonal birth control (eg, birth control pills), or penicillins (eg, amoxicillin) because their effectiveness may be decreased by Periostat

This may not be a complete list of all interactions that may occur. Ask your health care provider if Periostat may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Periostat:


Use Periostat as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Periostat by mouth on an empty stomach at least 1 hour before or 2 hours after eating.

  • Do not take an antacid that has aluminum, calcium, or magnesium in it; bismuth subsalicylate; iron; zinc; or multivitamins with minerals within 2 hours before or 2 hours after you take Periostat.

  • Do not eat or drink dairy products within 1 hour before or 2 hours after you take Periostat.

  • To clear up your infection completely, take Periostat for the full course of treatment. Keep taking it even if you feel better in a few days.

  • Drink plenty of nondairy fluid with Periostat to wash it down and avoid the risk of sore throat.

  • Take Periostat twice daily (every 12 hours), preferably in the morning and evening.

  • Continue to take Periostat even if you feel well. Do not miss any doses.

  • If you miss a dose of Periostat, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Periostat.



Important safety information:


  • Hormonal birth control (eg, birth control pills) may not work as well while you are using Periostat. To prevent pregnancy, use an extra form of birth control (eg, condoms).

  • Mild diarrhea is common with this type of medicine. However, a more serious form of diarrhea (pseudomembranous colitis) may rarely occur. This may develop while you use Periostat or within several months after you stop using it. Contact your doctor right away if stomach pain or cramps, severe diarrhea, or bloody stools occur. Do not treat diarrhea without first checking with your doctor.

  • Long-term or repeated use of Periostat may cause a second infection. Tell your doctor if signs of a second infection occur. Your medicine may need to be changed to treat this.

  • Periostat may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Periostat. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.

  • Tell your doctor or dentist that you take Periostat before you receive any medical or dental care, emergency care, or surgery.

  • Periostat may interfere with certain lab tests. Be sure your doctor and lab personnel know you are taking Periostat.

  • Lab tests, including liver function, kidney function, and complete blood counts, may be performed while you use Periostat. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Periostat should not be used in CHILDREN younger than 8 years old; permanent yellow-gray-brown tooth discoloration may occur.

  • PREGNANCY and BREAST-FEEDING: Periostat has been shown to cause harm to the fetus. If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of using Periostat while you are pregnant. Periostat is found in breast milk. Do not breast-feed while taking Periostat.


Possible side effects of Periostat:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Diarrhea; nausea; sensitivity to sunlight; stomach upset.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); bloody stools; chest pain; dark urine; decreased urination; fever, chills, or sore throat; moderate to severe sunburn; red, swollen, blistered, or peeling skin; severe diarrhea; severe or persistent headache; stomach pain or cramps; throat irritation; trouble swallowing; unusual bruising or bleeding; unusual joint pain; unusual tiredness; vaginal irritation or discharge; vision changes; yellowing of the skin or eyes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Periostat side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Periostat:

Store Periostat at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Periostat out of the reach of children and away from pets.


General information:


  • If you have any questions about Periostat, please talk with your doctor, pharmacist, or other health care provider.

  • Periostat is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Periostat. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Periostat resources


  • Periostat Side Effects (in more detail)
  • Periostat Use in Pregnancy & Breastfeeding
  • Drug Images
  • Periostat Drug Interactions
  • Periostat Support Group
  • 0 Reviews for Periostat - Add your own review/rating


  • Periostat Prescribing Information (FDA)

  • Periostat Advanced Consumer (Micromedex) - Includes Dosage Information

  • Doxycycline Professional Patient Advice (Wolters Kluwer)

  • Doxycycline Monograph (AHFS DI)

  • Doxycycline Prescribing Information (FDA)

  • Alodox Prescribing Information (FDA)

  • Doryx Prescribing Information (FDA)

  • Doxycycline Calcium Monograph (AHFS DI)

  • Monodox Prescribing Information (FDA)

  • Oracea Prescribing Information (FDA)

  • Oracea Consumer Overview

  • Vibramycin Prescribing Information (FDA)



Compare Periostat with other medications


  • Periodontitis

Thursday, 29 March 2012

Menjugate Kit (Sanofi Pasteur MSD Limited)





1. Name Of The Medicinal Product



MENJUGATE KIT 10 micrograms powder and solvent for suspension for injection



Meningococcal group C conjugate vaccine


2. Qualitative And Quantitative Composition








One dose (0.5 ml of the reconstituted vaccine) contains:


 


Neisseria meningitidis group C (strain C11) oligosaccharide



Conjugated to



Corynebacterium diphtheriae CRM-197 protein



adsorbed on aluminium hydroxide




10 micrograms



 



12.5 to 25.0 micrograms



0.3 to 0.4 mg Al 3+



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Powder and solvent for suspension for injection.



Powder (vial): white to off-white



Suspension (syringe): white opalescent



4. Clinical Particulars



4.1 Therapeutic Indications



Active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by Neisseria meningitidis group C.



The use of Menjugate Kit should be determined on the basis of official recommendations.



4.2 Posology And Method Of Administration



Posology



There are no data on the use of different Meningococcal group C conjugate vaccines within the primary series or for boosting. Whenever possible, the same vaccine should be used throughout.



Primary immunisation



Infants from 2 months of age up to 12 months: two doses, each of 0.5 ml, should be given with an interval of at least 2 months (See section 4.5 regarding co-administration of Menjugate Kit with other vaccines).



Children over the age of 12 months, adolescents and adults: a single dose of 0.5 ml.



Booster doses



It is recommended that a booster dose should be given after completion of the primary immunisation series in infants. The timing of this dose should be in accordance with available official recommendations. Information on responses to booster doses and on co-administration with other childhood vaccines is given in sections 5.1 and 4.5, respectively.



The need for booster doses in subjects primed with a single dose (i.e. aged 12 months or more when first immunised) has not yet been established (see section 5.1).



Method of Administration



Intramuscular injection. The vaccine (0.5 ml) is intended for deep intramuscular injection, preferably in the anterolateral thigh in infants and in the deltoid region in older children, adolescents and adults.



The vaccine must not be injected intravenously, subcutaneously or intradermally.



Menjugate Kit must not be mixed with other vaccines in the same syringe. Separate injection sites must be used if more than one vaccine is being administered.



4.3 Contraindications



Hypersensitivity to the active substance(s) or to any of the excipients of the vaccine, including diphtheria toxoid.



Persons who have shown signs of hypersensitivity after previous administration of Menjugate Kit.



As with other vaccines, administration of Menjugate Kit must be postponed in subjects with an acute severe febrile illness.



4.4 Special Warnings And Precautions For Use



Before the injection of any vaccine, the person responsible for administration must take all precautions known for the prevention of allergic or any other reactions. As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in case of a rare anaphylactic event following administration of the vaccine.



Prior to administration of any dose of Menjugate Kit, the parent or guardian must be asked about the personal history, family history, and recent health status of the vaccine recipient, including immunisation history, current health status and any adverse event after previous immunisations.



The benefits of vaccination with meningococcal group C conjugate vaccine must be reviewed in light of the incidence of N. meningitidis group C infection in a given population before the institution of a widespread immunisation campaign.



Menjugate Kit will not protect against meningococcal diseases caused by any of the other types of meningococcal bacteria (A, B, 29-E, H, I, K, L, W-135, X, Y, or Z, including non-typed). Complete protection against meningococcal group C infection cannot be guaranteed.



No data on the applicability of the vaccine for post-exposure outbreak control are as yet available.



In individuals deficient in producing antibodies, vaccination may not result in an appropriate protective antibody response. While HIV infection is not a contraindication, Menjugate Kit has not been specifically evaluated in the immunocompromised. Individuals with complement deficiencies and individuals with functional or anatomical asplenia may mount an immune response to meningococcal group C conjugate vaccines; however, the degree of protection that would be afforded is unknown.



Although symptoms of meningism such as neck pain/stiffness or photophobia have been reported there is no evidence that the vaccine causes meningococcal C meningitis. Clinical alertness to the possibility of co-incidental meningitis must therefore be maintained.



Conjugate vaccines containing Cross Reacting Material 197 (CRM197) should not be considered as immunising agents against diphtheria. No changes in the schedule for administering vaccines containing Diphtheria Toxoid are recommended.



Any acute infection or febrile illness is reason for delaying the use of Menjugate Kit except when, in the opinion of the physician, withholding the vaccine entails a greater risk. A minor afebrile illness, such as a mild upper respiratory infection, is not usually reason to defer immunisation.



The potential risk of apnoea and the need for respiratory monitoring for 48-72 hours should be considered when administering the primary immunisation series to very premature infants (born



The vaccine must not be injected intravenously, subcutaneously or intradermally.



Menjugate Kit has not been evaluated in persons with thrombocytopenia or bleeding disorders. The risk versus benefit for persons at risk of haemorrhage following intramuscular injection must be evaluated.



Parents must be informed of the immunisation schedule for this vaccine. Precautions such as useful antipyretic measures for this vaccine must be relayed to the parent or guardian and the need to report any adverse event must be stressed.



The tip cap of the syringe contains 10% Dry Natural Rubber. Although the risk for developing allergic latex reactions is very small, healthcare professionals are encouraged to consider the benefit risk prior to administering this vaccine to patients with know history of hypersensitivity to latex.



There are no data in adults aged 65 years and older (see section 5.1).



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Menjugate Kit must not be mixed with other vaccines in the same syringe. Separate injection sites must be used if more than one vaccine is being administered.



Administration of Menjugate Kit at the same time as (but, for injected vaccines, at a different injection site) the following vaccines in clinical studies did not reduce the immunological response to any of these other antigens:



- Polio (inactivated polio vaccine [IPV] and oral polio vaccine);



- Diphtheria [D] and Tetanus [T] toxoids alone or in combination with whole cell or acellular Pertussis [aP];



- Haemophilus Influenzae type B [Hib] conjugate vaccine;



- Hepatitis B [HBV] vaccine administered alone or at the same time as combined vaccine containing D, T, Hib, IPV and aP;



- Combined measles, mumps and rubella vaccine;



- 7-valent pneumococcal conjugate vaccine (Prevenar). The effect of concomitant administration of Menjugate with 7-valent pneumococcal conjugate vaccine (Prevenar) and a hexavalent vaccine [DTaP-HBV-IPV-Hib] on immune responses was assessed in infants vaccinated at median ages of approximately 2, 4.5 and 6.5 months. The potential for immune interference has not been assessed at other primary immunisation schedules.



Minor variations in GMT antibody titres were observed between studies; however, the clinical significance, if any, of these observations is not established.



In various studies with different vaccines, concomitant administration of meningococcal group C conjugates with combinations containing aP components (with or without IPV, hepatitis B surface antigen or Hib conjugates) has been shown to result in lower SBA GMTs compared to separate administrations or to co-administration with whole cell pertussis vaccines. The proportions reaching SBA titres of at least 1:8 or 1:128 are not affected. At present, the potential implications of these observations for the duration of protection are not known.



4.6 Pregnancy And Lactation



Pregnancy



There are no data on the use of this vaccine in pregnant women. Animal studies in rabbit at different stages of gestation have not demonstrated a risk to the foetus following administration of Menjugate Kit. Nevertheless, considering the severity of meningococcal group C disease pregnancy should not preclude vaccination when the risk of exposure is clearly defined.



Lactation



Information on the safety of the vaccine during lactation is not available. The benefit-risk ratio must be examined before making the decision as to whether to immunise during lactation.



4.7 Effects On Ability To Drive And Use Machines



No studies on the effects on the ability to drive and use machines have been performed.



Dizziness has been very rarely reported following vaccination. This may temporarily affect the ability to drive or use machines.



4.8 Undesirable Effects



The following descriptions of frequency have been defined: Very common (



Adverse Reactions from clinical trials



Adverse reactions reported across all age groups are provided below. Adverse reactions were collected on the day of vaccination and each day following for at least 3 and up to 6 days. The majority of reactions were self-limiting and resolved within the follow-up period.



In all age groups injection site reactions (including redness, swelling and tenderness/pain) were very common (ranging from 1 in 3 older children to 1 in 10 pre-school children). However, these were not usually clinically significant. Redness or swelling of at least 3cm and tenderness interfering with movement for more than 48 hours was infrequent where studied.



Fever of at least 38.0°C is common (ranging from 1 in 20 in infants and toddlers to 1 in 10 in pre-school children), but does not usually exceed 39.1°C, particularly in older age groups.



In infants and toddlers symptoms including crying and vomiting (toddlers) were common after vaccination. Irritability, drowsiness, impaired sleeping, anorexia, diarrhoea and vomiting (infants) were very common after vaccination. There was no evidence that these were related to Menjugate Kit rather than concomitant vaccines, particularly DTP.



Very commonly reported adverse events include myalgia and arthralgia in adults. Drowsiness was commonly reported in younger children. Headache was very common in secondary school children and common in primary school children.



Adverse reactions reported across all age groups










General disorders and administration site conditions


 


Very common




Injection site reactions (Redness, swelling and tenderness/pain)




Common




Fever



Additional reactions reported in infants (first year of life) and toddlers (second year of life)


















Gastrointestinal disorders


 


Very common




Diarrhoea and anorexia



Vomiting (infants)




Common




Vomiting (toddlers)



 

 


General disorders and administration site conditions


 


Very common




Irritability, drowsiness and impaired sleeping




Common




Crying



Additional reactions reported in older children and adults








Gastrointestinal disorders




 




Very common




Nausea (adults)








Musculoskeletal and connective tissue disorders


 


Very common




Myalgia and arthralgia










General disorders and administration site conditions


 


Very common




Malaise



Headache (secondary school children)




Common




Headache (primary school children)



Adverse Reactions from Post Marketing Surveillance (for all age groups)



The most commonly reported suspected reactions in post marketing surveillance include dizziness, pyrexia, headache, nausea, vomiting and faints.



The frequencies given below are based on spontaneous reporting rates, for this and other Meningococcal group C conjugate vaccines and have been calculated using the number of reports received as the numerator and the total number of doses distributed as the denominator.








Nervous system disorders



 


Very rare




Dizziness, convulsions including febrile convulsions, faints, hypoaesthesia and paraesthesia, hypotonia



There have been very rare reports of seizures following Menjugate Kit vaccination; individuals have usually rapidly recovered. Some of the reported seizures may have been faints. The reporting rate of seizures was below the background rate of epilepsy in children. In infants seizures were usually associated with fever and were likely to be febrile convulsions.



There have been very rare reports of visual disturbances and photophobia following vaccination with Meningococcal group C conjugate vaccines, usually in conjunction with other neurological symptoms like headache and dizziness.






Respiratory, thoracic and mediastinal disorders




Apnoea in very premature infants (








Gastrointestinal disorders



 


Very rare




Nausea, vomiting and diarrhoea








Skin and subcutaneous tissue disorders


 


Very rare




Rash, urticaria, pruritus, purpura, erythema multiforme and Stevens-Johnson Syndrome








Musculoskeletal and connective tissue disorders


 


Very rare




Myalgia and arthralgia








Immune system disorders



 


Very rare




Lymphadenopathy, anaphylaxis, hypersensitivity reactions including bronchospasm, facial oedema and angioedema.



Relapse of nephrotic syndrome has been reported in association with Meningococcal group C conjugate vaccines.



4.9 Overdose



No case of overdose has been reported. Since each injection is a single dose of 0.5 millilitres, overdose is unlikely.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Meningococcal vaccines, ATC code: J07A H.



Immunogenicity



No prospective efficacy trials have been performed.



The serum bactericidal assay (BCA) referenced in the text below used human serum as a source of complement. Serum bactericidal assay (BCA) results achieved with human serum as a source of complement are not directly comparable with those achieved with rabbit serum as a source of complement.



Data on the use of a 2-dose primary immunisation series are available from a clinical trial that compared a 2, 3, 4 month vaccination schedule to a 2, 4 month vaccination schedule in 241 infants. One month after completion of the primary series nearly all subjects had attained hBCA titres



Compared to licensed unconjugated meningococcal polysaccharide vaccines in clinical studies, the immune response induced by Menjugate Kit was shown to be superior in toddlers, children and adolescents, and was comparable in adults (see table). Additionally, unlike unconjugated polysaccharide vaccines, Menjugate Kit induces immunologic memory after vaccination, although the duration of protection is not yet established.



There are no data in adults aged 65 years or older.








































Comparison of the Percentage of Subjects with Antimeningococcal C Serum Bactericidal Titres


        


 




Age 1-2 years




Age 3-5 years




Age 11-17 years




Age 18-64 years


    


Menjugate



n=237




MenPS (1)



n=153




Menjugate



n=80




MenPS (1)



n=80




Menjugate



n=90




MenPS (2)



n=90




Menjugate



n=136




MenPS (2)



n=130


 


BCA %



(95% CI)



Human Complement




78%



(72-83)



 




19%



(13-26)



 




79%



(68-87)



 




28%



(18-39)



 




84%



(75-91)



 




68%



(57-77)



 




90%



(84-95)



 




88%



(82-93)



 



MenPS = licensed unconjugated Meningococcal polysaccharide vaccine.



(1) = groups A, C, W-135 and Y, containing 50μg of group C per dose.



(2) = groups A and C, containing 50μg of group C per dose.



No pharmacodynamic studies have been conducted with Menjugate Kit, in accordance with its status as a vaccine.



Post-marketing surveillance following an immunisation campaign in the UK



Estimates of vaccine effectiveness from the UK's routine immunisation programme (using various quantities of three meningococcal group C conjugate vaccines) covering the period from introduction at the end of 1999 to March 2004 demonstrated the need for a booster dose after completion of the primary series (three doses administered at 2, 3 and 4 months). Within one year of completion of the primary series, vaccine effectiveness in the infant cohort was estimated at 93% (95% confidence intervals 67, 99). However, more than one year after completion of the primary series, there was clear evidence of waning protection.



Up to 2007 the overall estimates of effectiveness in age cohorts from 1-18 years that received a single dose of meningococcal group C conjugate vaccine during the initial catch-up vaccination programme in the UK fall between 83 and 100%. The data show no significant fall in effectiveness within these age cohorts when comparing time periods less than a year or one year or more since immunisation.



5.2 Pharmacokinetic Properties



No pharmacokinetic studies have been conducted with Menjugate Kit, in accordance with its status as a vaccine.



5.3 Preclinical Safety Data



Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity and toxicity to reproduction (embryofetal studies).



6. Pharmaceutical Particulars



6.1 List Of Excipients



Vial containing MenC-CRM197 Conjugate



- Mannitol



- Sodium dihydrogen phosphate monohydrate



- Disodium phosphate – heptahydrate



Syringe containing aluminium hydroxide



- Sodium chloride



- Water for injections



6.2 Incompatibilities



This medicinal product must not be mixed with other medicinal products in the same syringe.



6.3 Shelf Life



3 years



Following reconstitution, the product should be used immediately.



The two components of the product may have different expiry dates. The outer carton bears the earlier of the two dates and this date must be respected. The carton and ALL its contents must be discarded on reaching this outer carton expiry date.



6.4 Special Precautions For Storage



Store in a refrigerator (2°C – 8°C).



Do not freeze. Keep the vial and the syringe in the outer carton in order to protect from light



6.5 Nature And Contents Of Container



Menjugate Kit is presented as a vial of powder (type I glass), with a stopper (bromobutyl rubber) and 0.6 ml of solvent in a syringe (type I glass) with a stopper (bromobutyl rubber) and a tip cap (either chlorobutyl rubber or styrene butadiene rubber)- pack size of 1,5 or 10 single doses.



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



The lyophilised vaccine will require preparation by reconstitution with aluminium hydroxide solvent.



Gently agitate the syringe containing the aluminium hydroxide solvent. Remove the tip cap from the syringe and attach a suitable needle. Use the whole content of the syringe (0.6 mL of suspension) to reconstitute the Meningococcal group C conjugate vaccine vial.



Gently shake the reconstituted vial until the vaccine is dissolved (this will ensure the antigen is bound to the adjuvant). Taking care not to withdraw the plunger completely out of the barrel of the syringe, withdraw the full contents of the vial into the syringe. Please note that it is normal for a small residual amount of liquid to remain in the vial following withdrawal of the dose. Please ensure that no air bubbles are present in the syringe before injecting the vaccine.



Following reconstitution the vaccine is a slightly opaque, colourless to light yellow suspension, free from visible foreign particles. In the event of any foreign particulate matter and/or variation of physical aspect being observed, discard the vaccine.



Any unused product or waste material should be disposed in accordance with local requirements.



7. Marketing Authorisation Holder



Novartis Vaccines and Diagnostics S.r.l.



Via Fiorentina 1



53100 Siena, Italy



8. Marketing Authorisation Number(S)



PL 13767/0023



9. Date Of First Authorisation/Renewal Of The Authorisation



01/03/2010



10. Date Of Revision Of The Text



01/03/2010




Tuesday, 27 March 2012

Infliximab


Pronunciation: in-FLIX-i-mab
Generic Name: Infliximab
Brand Name: Remicade

Patients who use Infliximab have an increased risk of developing serious and sometimes fatal infections (eg, bacterial, viral, or fungal infections; tuberculosis [TB]). Most patients who developed these infections were taking medicines that suppressed their immune systems (eg, methotrexate, corticosteroids).


TB may be caused by a new infection or by reactivation of a previous infection. You should be tested for TB infection before you start Infliximab. If you have a TB infection, treatment for TB should be started before you begin Infliximab. Tell your doctor right away if you develop symptoms of infection, such as fever, chills, persistent cough or sore throat, unusual vaginal discharge, painful or frequent urination, or a persistent feeling of being unwell. Tell your doctor if you have a history of chronic or recurrent infections.


Infliximab is a tumor necrosis factor (TNF) blocker. Lymphoma and other types of cancer have been reported in children and teenagers treated with TNF blockers. This has been fatal in some cases. Talk with your doctor for more information.


A rare type of cancer called hepatosplenic T-cell lymphoma (HSTCL) has rarely occurred in teenagers and young adults using TNF blockers, including Infliximab, to treat Crohn disease or ulcerative colitis. These cases have been fatal. Patients who developed this cancer were using Infliximab along with certain other medicines (azathioprine or 6-mercaptopurine). Tell your doctor if you have or have ever had any type of cancer.





Infliximab is used for:

Treating moderate to severe rheumatoid arthritis when used along with another medicine (methotrexate). It is also used to treat ankylosing spondylitis, psoriatic arthritis, and certain types of skin psoriasis (eg, plaque psoriasis). Infliximab is used to treat moderate to severe Crohn disease or ulcerative colitis in certain patients who have not received relief from other treatments. It may also be used for other conditions as determined by your doctor.


Infliximab is a monoclonal antibody. It works by blocking the action of a substance in the body called TNF. This may reduce the inflammation and immune responses caused by TNF.


Do NOT use Infliximab if:


  • you are allergic to any ingredient in Infliximab, including mouse-derived (murine) proteins

  • you have moderate to severe heart failure, unless your doctor has examined you and decided that you are able to take Infliximab. Certain doses of Infliximab should not be used in patients who have moderate to severe heart failure. Ask your doctor if you have questions about this information

  • you have an active infection

  • you are taking abatacept, an interleukin-1 blocker (eg, anakinra), or tocilizumab

Contact your doctor or health care provider right away if any of these apply to you.



Before using Infliximab:


Some medical conditions may interact with Infliximab. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have any type of infection, including bacterial or viral infection, fungal infection (eg, coccidiomycosis, histoplasmosis), TB infection, skin infection, or open cuts or sores on your body

  • if you have a history of chronic or recurrent infections, TB or a positive TB skin test, or if you have recently been around someone who has had TB

  • if you have conditions that may increase your risk of infection (eg, diabetes) or if you have traveled to or lived in an area where TB or other certain infections (eg, histoplasmosis, coccidioidomycosis, blastomycosis) are common

  • if you have a history of immune system problems (eg, weakened immune system), blood problems, bone marrow problems, or lymphoma or other cancers

  • if you have a history of liver problems (eg, hepatitis B), liver problems caused by drinking alcohol (alcoholic hepatitis), or hepatitis B virus reactivation when taking Infliximab or other TNF blockers

  • if you have any numbness or tingling or a disease that affects your nervous system (eg, multiple sclerosis [MS], Guillain-Barré syndrome, seizures)

  • if you have heart problems (eg, congestive heart failure)

  • if you have had phototherapy to treat psoriasis or other skin conditions

  • if you have recently received or are scheduled to receive a vaccine

  • if you have chronic obstructive pulmonary disease (COPD) or a history of smoking

  • if you have been taking another medicine to treat rheumatoid arthritis

Some MEDICINES MAY INTERACT with Infliximab. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Corticosteroids (eg, prednisone), costimulation modulators (eg, abatacept), immunosuppressants (eg, cyclosporine), interleukin-1 blockers (eg, anakinra), methotrexate, or tocilizumab because the risk of serious infections may be increased

This may not be a complete list of all interactions that may occur. Ask your health care provider if Infliximab may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Infliximab:


Use Infliximab as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Infliximab comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Infliximab refilled.

  • Infliximab is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Infliximab at home, a health care provider will teach you how to use it. Be sure you understand how to use Infliximab. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.

  • You may receive other medicines before each treatment with Infliximab to decrease the chance of an infusion-related reaction. Discuss any questions with your doctor.

  • If you miss a dose of Infliximab, contact your doctor right away.

Ask your health care provider any questions you may have about how to use Infliximab.



Important safety information:


  • Infliximab may cause dizziness. This effect may be worse if you take it with alcohol or certain medicines. Use Infliximab with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Do not receive a live vaccine (eg, measles, mumps) while you are using Infliximab. Talk with your doctor before you receive any vaccine.

  • Before you use Infliximab, discuss your vaccination history with your doctor to be sure that you are up to date on vaccinations.

  • Tell your doctor or dentist that you take Infliximab before you receive any medical or dental care, emergency care, or surgery.

  • Infliximab may lower the ability of your body to fight infection. Avoid contact with people who have colds or infections. Do not touch your eyes or the inside of your nose unless you have thoroughly washed your hands first. If you develop a fever, feel very tired, have a cough, or have flu-like symptoms, these could be signs that you may be getting an infection. If any of these symptoms occur, contact your doctor at once.

  • Infliximab may reduce the number of clot-forming cells (platelets) in your blood. Avoid activities that may cause bruising or injury. Tell your doctor if you have unusual bruising or bleeding. Tell your doctor if you have dark, tarry, or bloody stools.

  • Infliximab may increase the risk of developing a certain type of blood cancer (lymphoma) or other types of cancer. The risk may increase if you have used Infliximab for a long time. Tell your doctor if you have ever had lymphoma or another cancer. Contact your doctor right away if any symptoms appear, such as unusual lumps or swelling (eg, in your armpit, groin, or neck), night sweats, recurring fever, unusual tiredness, unexplained cough or breathlessness, persistent unexplained itching, or unexplained weight loss.

  • New or worsening nervous system disorders (eg, MS, Guillain-Barré syndrome, seizures) have occurred in patients who take Infliximab. Tell your doctor if you have a disease that affects your nervous system. Discuss any questions or concerns with your doctor.

  • Some patients who use Infliximab have developed new or worsening psoriasis. Tell your doctor right away if you notice any new or worsening skin problems (eg, red, flaky, or itchy skin patches).

  • Rarely, severe liver problems have occurred with the use of Infliximab. These liver problems may occur from 2 weeks to more than a year after starting Infliximab. Contact your doctor right away if you develop dark urine, pale stools, severe or persistent stomach pain, or yellowing of the skin or eyes.

  • Some patients receiving Infliximab have experienced an allergic reaction. Some allergic reactions have been severe. If such a reaction occurs, it has usually happened during treatment with Infliximab or within 2 hours after treatment. However, allergic reactions have also occurred up to 12 days after the use of Infliximab. Tell your doctor if symptoms such as fever, chills, rash, hives, headache, dizziness, chest pain, muscle or joint pain, swelling, sore throat, or trouble breathing or swallowing occur.

  • Rarely, temporary vision loss or a heart attack have been reported during treatment with Infliximab or within 2 hours after treatment. Tell your doctor right away if you experience vision loss or other vision changes; chest pain; numbness of an arm or leg; sudden, severe headache or vomiting; or fainting.

  • Infliximab may interfere with certain lab tests, including tests for TB infection. Be sure your doctor and lab personnel know you are using Infliximab.

  • Lab tests, including TB, liver function, and complete blood cell counts, may be performed while you use Infliximab. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Use Infliximab with caution in the ELDERLY; they may be more sensitive to its effects, especially the risk of infection.

  • Caution is advised when using Infliximab in CHILDREN; they may be more likely to develop certain side effects. These effects may include certain blood problems (eg, anemia, low white blood cell levels), blood in the stool, flushing, bone fracture, certain types of infection, and certain allergic reactions. Cases of unusual cancer have occurred in children and teenagers using Infliximab.

  • Infliximab should be used with extreme caution in CHILDREN younger than 6 years old; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: It is not known if Infliximab can cause harm to the fetus. If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Infliximab while you are pregnant. It is not known if Infliximab is found in breast milk. Do not breast-feed while taking Infliximab.


Possible side effects of Infliximab:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Back pain; headache; mild stomach pain or upset; pain, redness, or swelling at the injection site; runny or stuffy nose; tiredness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloody, black, or tarry stools; butterfly-shaped rash on the nose and cheeks; change in the amount of urine produced; change in the appearance of a mole; chest pain; dark urine; dizziness; fainting; fast, slow, or irregular heartbeat; flushing; joint or muscle pain; loss of appetite; nausea, vomiting, or diarrhea; numbness or tingling of the skin, arms, or legs; pale stools; red, swollen, blistered, or peeling skin; seizures; severe or persistent headache; severe or persistent stomach or back pain; shortness of breath; sudden, unexplained weight gain or loss; suicidal thoughts or attempts; swelling of the hands, legs, feet, or ankles; symptoms of infection (eg, fever or chills, painful or frequent urination, persistent cough or sore throat, flu-like symptoms, persistent feeling of being unwell, unusual vaginal discharge or odor, white patches in the mouth, red or painful skin); trouble swallowing; unusual bruising or bleeding; unusual lumps; unusual skin growths or other skin changes; unusual tiredness or weakness; very pale skin; vision changes; weakness in the arms or legs; yellowing of the skin or eyes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Infliximab side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Infliximab:

Infliximab is usually handled and stored by a health care provider. If you are using Infliximab at home, store Infliximab as directed by your pharmacist or health care provider. Keep Infliximab out of the reach of children and away from pets.


General information:


  • If you have any questions about Infliximab, please talk with your doctor, pharmacist, or other health care provider.

  • Infliximab is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Infliximab. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Infliximab resources


  • Infliximab Side Effects (in more detail)
  • Infliximab Use in Pregnancy & Breastfeeding
  • Infliximab Drug Interactions
  • Infliximab Support Group
  • 55 Reviews for Infliximab - Add your own review/rating


  • Infliximab Professional Patient Advice (Wolters Kluwer)

  • Infliximab Monograph (AHFS DI)

  • Remicade Consumer Overview

  • Remicade Prescribing Information (FDA)

  • infliximab Intravenous Advanced Consumer (Micromedex) - Includes Dosage Information



Compare Infliximab with other medications


  • Ankylosing Spondylitis
  • Behcet's Disease
  • Bullous Pemphigoid
  • Celiac Disease
  • Cogan's Syndrome
  • Crohn's Disease
  • Crohn's Disease, Acute
  • Crohn's Disease, Maintenance
  • Giant Cell Arteritis
  • Inflammatory Bowel Disease
  • Juvenile Idiopathic Arthritis
  • Kawasaki Disease
  • Neurosarcoidosis
  • Pemphigoid
  • Pemphigus
  • Polychondritis
  • Psoriasis
  • Psoriatic Arthritis
  • Pulmonary Fibrosis
  • Pyoderma Gangrenosum
  • Rheumatoid Arthritis
  • SAPHO Syndrome
  • Sarcoidosis
  • Sjogren's Syndrome
  • Subcorneal Pustular Dermatosis
  • Toxic Epidermal Necrolysis
  • Ulcerative Colitis
  • Uveitis

Monday, 26 March 2012

Loprox Suspension


Pronunciation: sye-kloe-PEER-ox
Generic Name: Ciclopirox
Brand Name: Generic only. No brands available.


Loprox Suspension is used for:

Treating athlete's foot, jock itch, ringworm, and other fungal infections of the skin. It may also be used for other conditions as determined by your doctor.


Loprox Suspension is an antifungal. It works by slowing the growth of the fungus.


Do NOT use Loprox Suspension if:


  • you are allergic to any ingredient in Loprox Suspension

Contact your doctor or health care provider right away if any of these apply to you.



Before using Loprox Suspension:


Some medical conditions may interact with Loprox Suspension. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

Some MEDICINES MAY INTERACT with Loprox Suspension. However, no specific interactions with Loprox Suspension are known at this time.


Ask your health care provider if Loprox Suspension may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Loprox Suspension:


Use Loprox Suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Clean the affected area with soap and water and dry thoroughly. Shake well before using a dose. Apply enough medicine to cover the affected area. Rub in gently. Do not cover unless directed by your doctor. Wash your hands immediately after using Loprox Suspension, unless your hands are part of the treated area.

  • To clear up your infection completely, use Loprox Suspension for the full course of treatment. Keep using it even if your symptoms have improved.

  • If you miss a dose of Loprox Suspension, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Loprox Suspension.



Important safety information:


  • Loprox Suspension is for external use only. Do not get it in your eyes, nose, or mouth. If you get it in your eyes, rinse right away with cool tap water.

  • Do not wrap or otherwise cover the treated area with bandages or wear tight-fitting clothing unless specifically directed by your doctor.

  • Be sure to use Loprox Suspension for the full course of treatment. If you do not, the medicine may not clear up your infection completely. The fungus could also become less sensitive to this or other medicines. This could make the infection harder to treat in the future.

  • If your symptoms do not get better within 4 weeks or if they get worse, check with your doctor.

  • Loprox Suspension should not be used in CHILDREN younger than 10 years old; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY AND BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Loprox Suspension while you are pregnant. It is not known if Loprox Suspension is found in breast milk. If you are or will be breast-feeding while you use Loprox Suspension, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Loprox Suspension:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Burning; itching at the application site.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blistering; oozing; swelling.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Loprox side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Loprox Suspension may be harmful if swallowed.


Proper storage of Loprox Suspension:

Store Loprox Suspension between 41 and 77 degrees F (5 and 25 degrees C). Store away from heat, moisture, and light. Keep Loprox Suspension out of the reach of children and away from pets.


General information:


  • If you have any questions about Loprox Suspension, please talk with your doctor, pharmacist, or other health care provider.

  • Loprox Suspension is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Loprox Suspension. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Loprox resources


  • Loprox Side Effects (in more detail)
  • Loprox Use in Pregnancy & Breastfeeding
  • Loprox Support Group
  • 2 Reviews for Loprox - Add your own review/rating


Compare Loprox with other medications


  • Cutaneous Candidiasis
  • Seborrheic Dermatitis
  • Tinea Corporis
  • Tinea Cruris
  • Tinea Pedis
  • Tinea Versicolor

Friday, 16 March 2012

Citracal 250 mg + D


Generic Name: calcium and vitamin D combination (KAL see um and VYE ta min D)

Brand Names: Calcarb with D, Calcet, Calcio Del Mar, Calcitrate with D, Calcium 600+D, Caltrate 600 with D, Caltrate 600 with D Plus Soy, Caltrate Colon Health, Citracal + D, Citracal 250 mg + D, Citracal Creamy Bites, Citracal Maximum + D, Citracal Petites, Citrus Calcium with Vitamin D, Dical-D, Os-Cal 250 with D, Os-Cal 500 + D, Os-Cal with D, Oysco 500 with D, Oysco D, Oyst-Cal-D, Oyster Shell Calcium with Vitamin D, Oyster-D, Oystercal-D, Posture-D H/P, Risacal-D


What is Citracal 250 mg + D (calcium and vitamin D combination)?

Calcium is a mineral that is found naturally in foods. Calcium is necessary for many normal functions of your body, especially bone formation and maintenance.


Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body.


Calcium and vitamin D combination is used to prevent or to treat a calcium deficiency.


Calcium and vitamin D combination may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about Citracal 250 mg + D (calcium and vitamin D combination)?


Before you take calcium and vitamin D combination, tell your doctor if you have kidney disease, past or present kidney stones, heart disease, circulation problems, a parathyroid disorder, or if you are pregnant or breast-feeding.


Avoid taking any other vitamin or mineral supplements that contain calcium or vitamin D without first talking to your doctor.

Before taking calcium and vitamin D combination, tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.


What should I tell my healthcare provider before taking Citracal 250 mg + D (calcium and vitamin D combination)?


If you have certain conditions, you may need a dose adjustment or special tests to safely use this medication. Before you take calcium and vitamin D combination, tell your doctor if you have:


  • kidney disease;

  • past or present kidney stones;


  • heart disease;




  • circulation problems; or




  • a parathyroid gland disorder.




Talk to your doctor before taking calcium and vitamin D combination if you are pregnant. Talk to your doctor before taking calcium and vitamin D combination if you are breast-feeding.

How should I take Citracal 250 mg + D (calcium and vitamin D combination)?


Take this medication exactly as prescribed by your doctor. Do not take it in larger amounts or for longer than recommended. Follow the directions on your prescription label.


Take the calcium and vitamin D regular tablet with a full glass of water.

The chewable tablet should be chewed before you swallow it.


Store calcium and vitamin D combination at room temperature away from moisture and heat.

What happens if I miss a dose?


Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine.

Overdose symptoms may include irregular heartbeat, stomach pain, nausea, vomiting, dry mouth, a metallic taste in your mouth, confusion, loss of appetite, constipation, weakness, headache, confusion, or fainting.


What should I avoid while taking Citracal 250 mg + D (calcium and vitamin D combination)?


Avoid taking any other vitamin or mineral supplements that contain calcium or vitamin D without first talking to your doctor.

Citracal 250 mg + D (calcium and vitamin D combination) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects may include:



  • an irregular heartbeat;




  • nausea, vomiting, or decreased appetite;




  • dry mouth;




  • constipation;




  • weakness;




  • headache;




  • a metallic taste;




  • muscle or bone pain; or




  • drowsiness.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Citracal 250 mg + D (calcium and vitamin D combination)?


Before taking calcium and vitamin D combination, tell your doctor if you are taking:



  • digoxin (Lanoxin, Lanoxicaps);




  • antacids containing calcium, aluminum, or magnesium;




  • other calcium supplements;




  • calcitriol (Rocaltrol) or other vitamin D supplements; or




  • a tetracycline antibiotic such as demeclocycline (Declomycin), doxycycline (Adoxa, Doryx, Oracea, Vibramycin), minocycline (Dynacin, Minocin, Solodyn, Vectrin), or tetracycline (Brodspec, Panmycin, Sumycin, Tetracap).



This list is not complete and there may be other drugs that can interact with calcium and vitamin D combination. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.



More Citracal 250 mg + D resources


  • Citracal 250 mg + D Use in Pregnancy & Breastfeeding
  • Citracal 250 mg + D Drug Interactions
  • Citracal 250 mg + D Support Group
  • 0 Reviews for Citracal + D - Add your own review/rating


Compare Citracal 250 mg + D with other medications


  • Dietary Supplementation
  • Osteoporosis


Where can I get more information?


  • Your pharmacist can provide more information about calcium and vitamin D combination.